# Gan & Lee Pharmaceuticals. clinical trials: 30 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 30 trials with Gan & Lee Pharmaceuticals. as lead sponsor, 15 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Gan & Lee Pharmaceuticals.: 30 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/gan-and-lee-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 15
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07945145 | A Pharmacokinetics Study of GZR33 Injection at Different Injection Sites | Gan & Lee Pharmaceuticals. | Phase 1 | Not yet recruiting | Healthy Participants | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945145) |
| November 6, 2026 | NCT07920783 | A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants | Gan & Lee Pharmaceuticals. | Phase 1 | Not yet recruiting | Atopic Dermatitis | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920783) |
| November 5, 2026 | NCT07918898 | Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous... | Gan & Lee Pharmaceuticals. | Phase 1 | Recruiting | Healthy Participants | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918898) |
| October 1, 2026 | NCT07851688 | A Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of GLR1075 Injection in Healthy... | Gan & Lee Pharmaceuticals. | Phase 1 | Not yet recruiting | Hypoalbuminemia in Cirrhotic Ascites | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851688) |
| August 25, 2026 | NCT07784699 | A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study... | Gan & Lee Pharmaceuticals. | Phase 1 | Recruiting | Healthy Subjects;Overweight or Obesity | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784699) |
| June 26, 2026 | NCT07670897 | Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants | Gan & Lee Pharmaceuticals. | Phase 1 | Not yet recruiting | T2D | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670897) |
| April 14, 2026 | NCT07527078 | Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes | Gan & Lee Pharmaceuticals. | Phase 3 | Recruiting | Type 2 Diabetes (T2DM) | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527078) |
| March 30, 2026 | NCT07501832 | Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP)... | Gan & Lee Pharmaceuticals. | Phase 3 | Recruiting | Obstructive Sleep Apnea (OSA) | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07501832) |
| March 25, 2026 | NCT07493057 | Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway... | Gan & Lee Pharmaceuticals. | Phase 3 | Recruiting | Obstructive Sleep Apnea (OSA) | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493057) |
| March 12, 2026 | NCT07468396 | A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer | Gan & Lee Pharmaceuticals. | Phase 1 | Not yet recruiting | Prostate Cancer | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468396) |
| February 4, 2026 | NCT07387003 | Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes | Gan & Lee Pharmaceuticals. | Phase 2 | Not yet recruiting | Type 2 Diabetes (T2DM) | 345 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07387003) |
| January 21, 2026 | NCT07355738 | Bioequivalence Study of GZR18 Injection Before and After CMC Change | Gan & Lee Pharmaceuticals. | Phase 1 | Completed | Obesity&T2D | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07355738) |
| January 12, 2026 | NCT07334496 | A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects | Gan & Lee Pharmaceuticals. | Phase 1 | Not yet recruiting | Biosimilarity | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07334496) |
| December 18, 2025 | NCT07292441 | Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss | Gan & Lee Pharmaceuticals. | Phase 3 | Completed | Overweight or Obesity | 224 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292441) |
| September 25, 2025 | NCT07193147 | Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment | Gan & Lee Pharmaceuticals. | Phase 1 | Active not recruiting | Diabetes | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07193147) |
| September 10, 2025 | NCT07165223 | A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin | Gan & Lee Pharmaceuticals. | Phase 3 | Recruiting | Diabetes | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07165223) |
| September 2, 2025 | NCT07150975 | Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight... | Gan & Lee Pharmaceuticals. | Phase 3 | Recruiting | Obesity/Overweight in Adult | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07150975) |
| August 27, 2025 | NCT07144098 | Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function | Gan & Lee Pharmaceuticals. | Phase 1 | Completed | Obesity/Overweight | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07144098) |
| August 26, 2025 | NCT07141030 | Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function | Gan & Lee Pharmaceuticals. | Phase 1 | Completed | Obesity/Overweight | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07141030) |
| August 19, 2025 | NCT07128888 | Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection | Gan & Lee Pharmaceuticals. | Phase 1 | Completed | Obesity or Overweight | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128888) |
| August 13, 2025 | NCT07119450 | The Study of \[14C\] GZR18 | Gan & Lee Pharmaceuticals. | Phase 1 | Completed | Overweight, Obese, Obesity | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07119450) |
| July 8, 2025 | NCT07055386 | A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus | Gan & Lee Pharmaceuticals. | Phase 2 | Active not recruiting | Type 2 Diabetes Mellitus (T2DM) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07055386) |
| May 16, 2025 | NCT06974487 | A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in... | Gan & Lee Pharmaceuticals. | Phase 1 | Not yet recruiting | Type 2 Diabetes | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06974487) |
| January 17, 2025 | NCT06780410 | A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid | Gan & Lee Pharmaceuticals. | Phase 3 | Completed | Primary Hyperlipidemia | 245 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06780410) |
| January 16, 2025 | NCT06778967 | A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus | Gan & Lee Pharmaceuticals. | Phase 3 | Completed | Type 2 Diabetes Mellitus (T2DM) | 1,133 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06778967) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 2 | 2 |
| Phase 3 | 13 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 10 |
| Not yet recruiting | 8 |
| Recruiting | 7 |
| Active not recruiting | 5 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Obesity | 9 |
| Diabetes Mellitus, Type 2 | 6 |
| Overweight | 6 |
| Diabetes Mellitus | 5 |
| Insulin Resistance | 3 |
| Sleep Apnea, Obstructive | 2 |
| Hypoalbuminemia | 1 |
| Dermatitis, Atopic | 1 |
| Prostatic Neoplasms | 1 |
| Hyperlipidemias | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Occupational medicine clinics in the United States](https://specstream.ai/data/businesses/occupational-medicine-clinics/united-states)
- [Handyman services in the United States](https://specstream.ai/data/businesses/handyman-services/united-states)
- [Construction companies in the United States](https://specstream.ai/data/businesses/construction-companies/united-states)
- [Appliance manufacturers in the United States](https://specstream.ai/data/businesses/appliance-manufacturers/united-states)
- [Shutters companies in the United States](https://specstream.ai/data/businesses/shutters-companies/united-states)
